PDCD1LG2 and neoplasm: Thus, we can speculate that the addition of anti-PDL2 Ab to anti-PDL1 therapy soon after immunogenic chemotherapy maximizes the ability of CD103+DCs to cross-present tumor antigens by shielding two non-redundant immunoinhibitory signals, ultimately leading to an efficient and long-lasting CD8+T cell stimulation.